Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Roth Mkm cut their price objective on shares of Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, September 23rd.

Aptevo Therapeutics Trading Up 15.3 %

Shares of Aptevo Therapeutics stock opened at $0.31 on Friday. The business’s 50 day moving average price is $0.22 and its 200 day moving average price is $0.41. Aptevo Therapeutics has a one year low of $0.14 and a one year high of $10.80.

Hedge Funds Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics at the end of the most recent reporting period. 8.06% of the stock is currently owned by institutional investors and hedge funds.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.